SANTA ANA, CA, Clinical-stage biopharmaceutical company focused on the development of novel immunotherapies, today announced the closing of a $22 million Series C. more...
CAMBRIDGE, MA, Clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, has closed an oversubscribed $63M Series B. more...